Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lipocine (LPCN) Payables (2016 - 2025)

Lipocine's Payables history spans 14 years, with the latest figure at $861452.0 for Q3 2025.

  • For Q3 2025, Payables rose 201.9% year-over-year to $861452.0; the TTM value through Sep 2025 reached $861452.0, up 201.9%, while the annual FY2024 figure was $271696.0, 80.54% down from the prior year.
  • Payables reached $861452.0 in Q3 2025 per LPCN's latest filing, up from $442994.0 in the prior quarter.
  • In the past five years, Payables ranged from a high of $1.4 million in Q4 2023 to a low of $271696.0 in Q4 2024.
  • Average Payables over 5 years is $691975.2, with a median of $630456.0 recorded in 2022.
  • Peak YoY movement for Payables: crashed 80.54% in 2024, then soared 201.9% in 2025.
  • A 5-year view of Payables shows it stood at $1.3 million in 2021, then tumbled by 53.43% to $600388.0 in 2022, then skyrocketed by 132.51% to $1.4 million in 2023, then plummeted by 80.54% to $271696.0 in 2024, then soared by 217.06% to $861452.0 in 2025.
  • Per Business Quant, the three most recent readings for LPCN's Payables are $861452.0 (Q3 2025), $442994.0 (Q2 2025), and $360239.0 (Q1 2025).